Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 36Cholangiocarcinoma 11Carcinoma, Renal Cell 10Stomach Neoplasms 5Liver Neoplasms 5Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasm Metastasis 2Liver Diseases 2Kidney Neoplasms 2Cirrhosis, Familial, with Pulmonary Hypertension 2Breast Neoplasms 2Advanced Solid Tumor 2von Hippel-Lindau Disease 1Urogenital Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Penile Neoplasms 1

Interventions

relacorilant 1pembrolizumab 1lenvatinib 1Papanicolaou Test 1Blood Specimen Collection 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ovarian Diseases × lenvatinib × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡